Global Research Trends

Monday, 31 May 2021

Microtomes Market To Surpass US$ 208.4 Million By 2027 - Coherent Market Insights

Global Microtomes Market, by Equipment Type (Instruments (Rotary Microtome, Vibrating Microtome, Cryostat Microtome, Freezing Microtome, and Others) and Accessories), by Technology/Interventions (Fully Automated Microtomes, Semi-automated Microtomes, and Manual Microtomes), by Application (Disease Diagnosis and Medical Research), by End User (Hospitals, Ambulatory Surgical Centers, Research Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 128.5 million in 2019 and is expected to exhibit a CAGR of 6.2% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing focus of manufacturers on development and launching of innovative microtomes is expected to drive growth of the global microtomes market. For instance, in August 2018, Leica Microsystems, a manufacturer and developer of microscopes and scientific instruments, launched ARTOS 3D ultramicrotome, a powerful ARray TOmography Solution for 3D imaging applications. Moreover, in May 2018, Leica Microsystems introduced the new family of rotary microtome including HistoCore BIOCUT, HistoCore MULTICUT, and HistoCore AUTOCUT clinical microtomes to its histology equipment and consumables business segment. Thus, availability of such wide range of rotary microtomes is expected to significantly drive growth of the rotary microtomes segment in the global microtomes market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3783

Browse 42 Market Data Tables and 40 Figures spread through 185 Pages and in-depth TOC on "Global Microtomes Market, by Equipment Type (Instruments (Rotary Microtome, Vibrating Microtome, Cryostat Microtome, Freezing Microtome, and Others) and Accessories), by Technology/Interventions (Fully Automated Microtomes, Semi-automated Microtomes, and Manual Microtomes), by Application (Disease Diagnosis and Medical Research), by End User (Hospitals, Ambulatory Surgical Centers, Research Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027"

The increasing prevalence of chronic disorders such as cancer, diabetes, and heart diseases, where there is requirement of studying the histopathology of patients’ tissue sample, is expected to drive growth of the market. For instance, in cancer, histopathology/cytopathology influences the prognosis and the selection of anti-cancer treatments. According to American Cancer Society estimation, in 2020, around 1,806,590 new cases of cancer are projected to be diagnosed in the U.S. Such increasing number of cases is expected to increase tissue collection and preparation procedures, thereby driving growth of the market.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/microtomes-market-3783

Key takeaways of the Global Microtomes Market:

The global microtomes market is expected to exhibit a CAGR of 2% during the forecast period (2020-2027), owing to increasing initiatives by key players to launch innovative dental workflow system in the market. For instance, in November 2018, Sakura Finetek USA launched Accu-Cut SRM 300 LT manual microtome.

The establishment of new research and diagnostic laboratories is expected to significantly drive growth of the microtome market, as it is expected to increase demand for all histopathology instruments such as microtomes, microscopes, and other accessories in the laboratories. For instance, in November 2013, University of Southern California (USC) and The Saban Research Institute of Children’s Hospital Los Angeles launched Translational Biomedical Imaging Lab (TBIL) equipped with microscope, High Speed Microscopy Lab, extended Volume Imaging Lab with an integrated microtome and laser-scanning microscope, and the Quantitative Image Analysis and Visualization Suite.

Major players operating in the global microtomes market include LLS ROWIAK LaserLabSolutions GmbH, Leica Biosystems Nussloch GmbH, MEDITE GmbH, SLEE medical GmbH, Boeckeler Instruments, Nanolytik, S.M. Scientific Instruments Pvt. Ltd., MICROS Austria Produktions-und Handelsges.m.b.H, AGD Biomedicals (P) Ltd., Alltion, Amos Scientific Pty Ltd, and Thermo Fisher Scientific

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3783

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Androgen Replacement Therapy Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Global Androgen Replacement Therapy Market, by Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,965.5 million in 2021 and is expected to exhibit a CAGR of 7.8% during the forecast period (2021-2028).

Product approval by regulatory authorities is expected to drive growth of the global androgen replacement therapy market during the forecast period. For instance, in October 2018, Antares Pharma received the U.S. FDA approval for XYOSTED (testosterone enanthate) injection. XYOSTED is the first U.S. FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. XYOSTED has been approved in three dosage strengths- 50 mg, 75 mg, and 100 mg, and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Key players are focused on development and launch of new advanced androgen replacement therapies in the market, which is expected to contribute significantly to the androgen replacement therapy market growth. For instance, in October 2018, Perrigo Company plc. announced the launch of an AB-rated generic version of Androgel Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g packet, and 20.25mg/1.25g actuation pump).

Global Androgen Replacement Therapy Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 146 million cases and 3.1 million deaths due to coronavirus (COVID-19) were reported up till April 25th, 2021 across the globe.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3787

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. The private healthcare sector is one of the sectors which has been majorly affected by the pandemic. The lockdown in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatient’s visits among others.

Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. The COVID-19 pandemic has affected the economy in three main ways: 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets.

Supply chain and manufacturing activities in India, China, the U.S., and others have been disrupted due to lockdowns. Whereas, countries such as Thailand, Indonesia, Singapore, and others are facing problems with transportation of drugs and medications. The COVID-19 pandemic is expected to slightly disrupt the R&D activities in the androgen replacement therapy market.

Browse 39 Market Data Tables and 22 Figures spread through 191 Pages and in-depth TOC on Global Androgen Replacement Therapy Market, by Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), by Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787

Several market players are focused on acquisition of commercial rights to expand their product portfolio and gain maximum share of market. For instance, in April 2016, Aytu BioScience, Inc., announced the exclusive licensing of its third commercial-stage urology product in just 11 months, with the execution of a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals Corporation for the U.S. commercial rights to Natesto (testosterone) Nasal Gel. Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA), as a replacement therapy for men diagnosed with hypogonadism.

Key Takeaways of the Androgen Replacement Therapy Market:

The global androgen replacement therapy market is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028), owing to growth in potential markets, especially in Europe. While, North America accounted for the major market share over the forecast period (2021 -2028).

Market players are indulged in launching of products, which is expected to drive growth of the global androgen replacement therapy market over the forecast period. For instance, in April 2020, Xiromed LLC launched Testosterone Gel 1.62% Metered Dose Pump (20.25mg/1.25g pump actuation), an AB-rated generic version of AndroGel 1.62%. AndroGel 1.62% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Some of the major players operating in the global androgen replacement therapy market include AbbVie, Inc., Bayer AG, Endo Pharmaceuticals, Plc., Eli Lilly and Company, Kyowa Kirin International Plc., Novartis International AG, Pfizer Inc., Clarus Therapeutics, Inc., Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Sawai pharmaceutical Co., Ltd., Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., and Simple Pharma.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3787

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Europe Gelatin and Bone Glue Market Size Share Trends Forecast 2026

Bone glues are of two types – synthetic and natural bone glues. Synthetic bone glues considered in this report are cyanoacrylate, methacrylate, polyurethane foams, bisphenol-A glycidyl dimethacrylate, epoxy resins, and zinc polycarboxylate. Natural bone glues are biologically derived adhesives and sealants i.e. fibrin sealants and its variants. Other groups include gelatin-aldehydes, protein-aldehydes, collagen-based adhesives, polysaccharide-based adhesives, mussel adhesive proteins, and other biomimetic glues.

Statistics:

Europe Gelatin and Bone Glue Market is estimated to account for US$ 310.4 Mn in terms of value by the end of 2027.

Europe Gelatin and Bone Glue Market: Drivers

Increasing number of joint replacement procedures is expected to propel growth of Europe gelatin and bone glue market over the forecast period. For instance, according to National Joint Registry 15th Annual Report 2018, 252,250 joint replacements were performed in England, Wales, Northern Ireland and the Isle of Man, in 2018, accounting for 10,000 additional joint replacement operations than recorded in 2017.

Europe Gelatin and Bone Glue Market: Opportunities

R&D of novel bioceramics is expected to offer lucrative growth opportunities for players in market. For instance, in December 2018, researchers from Uppsala University, Sweden, reported development of a new class of bioinspired calcium phosphate cementsthat can glue tissues together and bond tissues to metallic and polymeric biomaterials.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3793

Europe Gelatin and Bone Glue Market: Restraints

Stringent regulations for approval of new products and low efficiency of some gelatin and surgical sealants is expected to limit growth of the market. For instance, cyanoacrylate glues are suitable for most surgical procedures. However, they have not been yet cleared for inward application because of their toxicity.

Key Takeaways:

Europe gelatin and bone glue market was valued at US$ 193.0 Mn in 2019 and is forecast to reach a value of US$ 310.4 Mn by 2027 at a CAGR of 6.1% between 2020 and 2027. Increasing adoption of expansion strategies from major players operating in the market is expected to assist the growth of the market.

Bone Glues segment held dominant position in Europe gelatin and bone glue market in 2019, accounting for 68.1% share in terms of value, followed by Gelatin, respectively. Increasing number of joint replacement procedures is expected to propel growth of the segment during the forecast period.

Arthroplasty segment held dominant position in Europe gelatin and bone glue market in 2019, accounting for 39.7% share in terms of value, followed by Sports Injury, respectively. Increasing prevalence of bone related disorders is expected to propel growth of the market during the forecasted period

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/europe-gelatin-and-bone-glue-market-3793

Market Trends

Increasing number of ocular injuries is expected to boost growth of Europe gelatin and bone glue market. For instance, according to the study, “Ocular injuries caused by less-lethal weapons in France”, published in November 2019, in The Lancet, between February 2016 and August 2019, 43 cases of ocular injuries were identified in Paris.

In March 2019, Regen Lab challenged the European Patent Office’s disapproval for its patent for autologous biological glue earlier granted by British Court.

Europe Gelatin and Bone Glue Market: Competitive Landscape

Major players operating in include, Johnson & Johnson, Baxter International Inc., CryoLife, Inc., Becton, Dickinson and Company, Luna Innovations Incorporated, B. Braun Melsungen AG, Cohera Medical, Inc., Integra LifeSciences Corporation, Tissuemed Ltd., and Chemence Medical, Inc.

Europe Gelatin and Bone Glue Market: Key Developments

April 2019: CryoLife, Inc participated in the 18th Annual Needham Healthcare Conference in New York

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3793

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market -2027

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 211.3 million in 2020 and is expected to exhibit a CAGR of 10.5% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing number of product approvals and launches, adoption of methicillin resistant staphylococcus aureus (MRSA) testing systems, and mergers and acquisitions by key players are the major factors that are expected to drive growth of the Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market during the forecast period.

Product approvals by regulatory bodies are expected drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market during the forecast period. For instance, in December 2019, the US Food and Drug Administration (FDA) granted marketing approval for Roche Molecular Systems’ cobas vivoDx MRSA, a diagnostic test that detects colonisation of Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. The cobas vivoDx MRSA test uses a new bacteriophage technology based on bioluminescence to detect MRSA from nasal swab samples in as less as 5 hours compared to 24-48 hours for conventional culture. The cobas vivoDx MRSA diagnostic test may allow healthcare professionals to evaluate patients for colonization with MRSA bacteria more quickly than traditional culture-based techniques.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3803

Key players are focused on development and launch of new methicillin resistant staphylococcus aureus (MRSA) testing systems in the market which is expected to contribute significantly to the methicillin resistant staphylococcus aureus (MRSA) testing systems market growth. For instance, in June 2019, Spindiag, a medtech startup company based in Germany, announced that it had expanded financing of its first Series A funding for MRSA testing systems. A proprietary microfluidic technology was first researched at the company’s main institute. Spindiag is developing a sustainable platform to diagnose infections and as a first product, a rapid test for multidrug-resistant bacteria. Furthermore, the additional money will enable industrializing the production and securing CE-IVD approval for the EU market of an MRSA (methicillin-resistant Staphylococcus aureus) rapid test is planned for launch in 2020. Spindiag intends to use US$ 4.3 million to execute its market entry in Europe in 2020.

The increasing awareness about methicillin resistant staphylococcus aureus (MRSA) infections and prevention efforts by hospitals, governments, and other organizations is expected to accelerate the methicillin resistant staphylococcus aureus (MRSA) testing systems market growth in the near future. The U.S. Department of Health and Human Services and Centers for Disease Control and Prevention are working with healthcare facilities to meet the goals in the 2013 National Action Plan to Prevent Healthcare-Associated Infections and reduce bloodstream infections caused by MRSA by 50% by 2020 using the 2015 baseline.

Browse 35 Market Data Tables and 29 Figures spread through 177 Pages and in-depth TOC on Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test, and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/methicillin-resistant-staphylococcus-aureus-testing-systems-market-3803

Several market players are focused on acquisitions and mergers to expand their product portfolio and gain a maximum share in the market. For instance, in September 2017, Abbott Laboratories announced that they have completed the acquisition of Alere, Inc. for US$ 5.3 billion. With the acquisition of Alere, the company also obtained the subsidiary Arriva Medical, which is the largest mail-order diabetic supplier. This acquisition has established Abbott as the global leader in point of care testing in vitro diagnostics market and further strengthened the company's diagnostics presence.

Key Takeaways of the Methicillin Resistant Staphylococcus Aureus (MRSA) testing systems market:

The methicillin resistant staphylococcus aureus (MRSA) testing systems market is expected to exhibit a CAGR of xx% during the forecast period (2020-2027) owing to increasing product approvals and product launches.

Among product type, the instruments segment is expected to hold a major revenue share in 2027 owing to the increasing product approvals and launches. For instance, in March 2014, AdvanDx announced that it has submitted its new mecA XpressFISH test to the U.S. Food and Drug Administration for 510(k) clearance for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) from S. aureus positive blood cultures. This assay will provide physicians with a new way to rapidly identify MRSA enabling them to implement appropriate treatment for patients with bloodstream infections.

Major players operating in the methicillin resistant Staphylococcus aureus (MRSA) testing systems market are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3803

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Meperidine (Demerol) Market Size, Share, Outlook, Opportunity Analysis, 2019– 2027

Global Meperidine (Demerol) Market, by Dosage Form (Tablets, Injection, and Syrup), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,089.1 Mn in 2020 and is expected to increase to US$ 2,784.3 Mn by 2027, witnessing a CAGR of 4.2% during the forecast period (2020-2027) as highlighted in a new report published by Coherent Market Insights.

Manufacturers are engaged in developing new meperidine (Demerol) products for pain management, which has led to an increase in product launches and approvals. This is expected to boost the global meperidine (Demerol) market growth. For instance, in 2015, Epic Pharma, launched generic meperidine in the U.S. for the relief of moderate to severe pain in 50-mg and 100-mg dosage strengths in 100 count bottles. Moreover, manufacturers such as Pfizer, Inc., Hikma Pharmaceuticals, and others also offer branded as well as generic meperidine in the market.

Browse 24 Market Data Tables, and 26 Figures spread through 140 Pages and in-depth TOC on Global Meperidine (Demerol) Market, by Dosage Form (Tablets, Injection, and Syrup), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3816

The rising prevalence of chronic diseases such as cancer and pain associated diseases is expected to result in higher use of potent opioid medications for pain management. Moreover, meperidine is used as a drug for post-operative pain. Meperidine has advantages such as providing very short analgesia which is appropriate for minimally invasive surgeries. Moreover, the growing preference for minimally invasive surgeries is also expected to support growth of the market during the forecast period. For instance, according a study published in January 2020 in Jama Network (The Journal of the American Medical Association), the use of robotic surgeries for all procedures had increased from 1.8% to 15.1% from 2012 to 2018 in the U.S. These factors are expected to support global meperidine (Demerol) market growth during the forecast period.

The increasing number of surgical procedures are expected to drive the global meperidine (Demerol) market growth

Opioids such as meperidine are used as pre-anesthetic medication in the surgical procedure, and are also used as part of anesthesia to prevent pain after surgical procedure. Opioids are also used in surgical treatment related to cancer. They are also used in cardiovascular procedures to obtain the relief from post-surgical treatment pain. The increasing number of surgeries worldwide is expected to support growth of the market during the forecast period. For instance, according to Eurostat, 2019, there were at least 1.4 million caesarean sections performed in the EU in 2017. Moreover, pain management related to cancer disease, back pain, neuropathic pain, migraine, osteoarthritis, and pain which occurs after the surgical procedures also involves use of opioids such as meperidine. The rising prevalence of such diseases is expected to support global meperidine (Demerol) market growth during the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/meperidine-market-3816

Key takeaways of the global meperidine (Demerol) market:

The global meperidine (Demerol) market is expected to exhibit a CAGR of 4.2% during the forecast period (2020-2027) owing to product approvals and launches as well as increasing prevalence of chronic diseases requiring surgical intervention.

On the basis of dosage form, the injection segment is expected to hold a dominant position in the global meperidine (Demerol) market during the forecast period owing to high use in post-operative pain management and post pregnancy pain management.

Based on distribution channel, the hospital pharmacies segment is expected to witness significant growth due to increasing use of meperidine in post-operative pain management as it would be sold through hospital pharmacies.

Some of the major players involved in the global meperidine (Demerol) market are Pfizer, Inc., Hikma Pharmaceuticals USA Inc., Epic Pharma, Inc., and Vintage Pharmaceuticals, Inc.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3816

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Friday, 28 May 2021

Sarcoma Biopsy Market To Surpass US$ 247.47 Million By 2027 - Coherent Market Insights

Global Sarcoma Biopsy Market, by Product Type (Reusable Device and Disposable Devices), by End User (Hospitals, Ambulatory Surgical Centers, and Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 192.55 million in 2019, and is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Global sarcoma biopsy market is expected to witness to significant growth during the forecast period, owing to increasing technological advancements in the field of biopsy. For instance, in November 2015, Cook Medical launched its new EchoTip ProCore 20 gage needle with ReCoil Stylet, which will help the physicians to collect the blood samples from the rom difficult anatomical locations. Ecotip ProCore has core-trap technology, which will allow the physicians to collect samples during the minimally invasive procedure.

Furthermore, in October 2017, European Commission approved the acquisition of C.R Bard by Becton Dickinson Company. This acquisition helped the company to manufacture new medical devices and technology, which will be utilized to cure many serious conditions such as cancer.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3819

Browse 26 Market Data Tables and 25 Figures spread through 151 Pages and in-depth TOC on Global Sarcoma Biopsy Market, by Product Type (Reusable Device and Disposable Devices), by End User (Hospitals, Ambulatory Surgical Centers, and Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027"

Increasing prevalence of osteosarcoma is expected to drive growth of the global sarcoma biopsy market.

Osteosarcoma is the most common type of cancer affecting bones, and it mostly occurs in children and young adults. On the basis of cells, osteosarcoma is classified as high-, intermediate- and low-grade. For instance, according to the American Cancer Society, IN January 2020, around 800 to 900 new cases of osteosarcoma are diagnosed in the U.S. each year, with around 50% occurs in children and teenagers.

Global Sarcoma Biopsy Market– Regional Analysis

North America accounted for the largest market share in the global sarcoma biopsy market, owing to rising healthcare expenditure in the U.S. For instance, according to the Committee for a Responsible Federal Budget, in 2017, the U.S. spent around US $ 3.5 trillion, or 18% of the total GDP, on health expenditures, which is more than twice the average among developed countries.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/sarcoma-biopsy-market-3819

Key Takeaways of the Global Sarcoma Biopsy Market:

The global sarcoma Biopsy market is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027), owing to increasing technological advancements in the field of biopsy.

Kaposi sarcoma being one of the sarcoma condition is much more common among men than women, and is rarely observed among children. For instance, according to the American Cancer Society (ACS), February 2016 data findings, around 1 in 200 transplant patients in the U.S. suffer from Kaposi sarcoma. In the U.S.

Major players operating in the global sarcoma biopsy market include R. Bard, Inc., Becton, Dickinson and Company, Argon Medical Devices, InVivo Therapeutics Corporation, Cook Medical Incorporated, UROMED, and Sterylab

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3819

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Latex Probe Cover Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Global Latex Probe Cover Market, by Type (Disposable and Reusable), by Application (Endocavity Probe Covers, Ultrasound Probe Covers, Transrectal and Transvaginal Probe Covers, General Purpose Probe Covers, and Other), by End User (Hospitals, Ambulatory Surgical Centers, Clinics, and Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is expected to be valued at US$ 552.76 million in 2020 and is expected to exhibit a CAGR of 7.2% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The rising incidence of cross infections due to ultrasound procedures is expected to boost growth of the latex probe cover market over the forecast period. For instance, according to the data published in the American Journal of Infection Control in 2018, ultrasound procedures such as transvaginal, transrectal, intracavity, tranesophageal, and post-operative wounds carry significant risk of cross infections. Moreover, a study conducted in 2017 by the NHS Health Scotland showed that patients opting for transvaginal scan had 41% higher probability of getting positive bacterial cultures and 26% are more likely to be prescribed with antibiotics within 30 days of ultrasound. Similarly, for patients undergoing transrectal ultrasounds, the probability of getting positive cultures increased up to 75%.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3822

Browse 27 Market Data Tables and 26 Figures spread through 165 Pages and in-depth TOC on “Latex Probe Cover Market”- Global Forecast to 2027, by Type (Disposable, and Reusable), by Application (Endocavity Probe Covers, Ultrasound Probe Covers, Transrectal and Transvaginal Probe Covers, General Purpose Probe Covers, and Other), by End User (Hospitals, Ambulatory Surgical Centers, Clinics, and Diagnostic Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

The increasing prevalence of cardiovascular diseases (CVD) is expected to propel growth of the latex probe cover market over the forecast period. For instance, according to the Australian Bureau of Statistics (ABS) 2017–18 National Health Survey around 1.2 million adults (18 years and over) suffered from cardiovascular diseases (CVD) in Australia in 2017-18.

Key Takeaways of the Global Latex Probe Cover Market:

The global latex probe cover market is expected to exhibit a CAGR of 7.2% over the forecast period, owing to increasing prevalence of cardiovascular diseases (CVD). For instance, according to the Health Survey for England 2017 Cardiovascular Diseases, 14% of people aged 16 and over, reported having cardiovascular disease (CVD).

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/latex-probe-cover-market-3822

Among type, disposable segment accounted for largest market share in 2019, owing to increased prevalence of cancer. According to the American Cancer Society's (ACS) publication, Cancer Facts & Figures 2020, around 73,750 adults is expected to be diagnosed with kidney cancer in the U.S. in 2020.

Among application, ultrasound probe cover segment accounted for largest market share in 2019, owing to increasing prevalence of prostate cancer. For instance, according to the Cancer Research UK around 48,487 cases of prostate cancer were reported in the U.K. during 2015-2017.

Key players operating in the global latex probe cover market include Cardinal Health, Inc., Parker Laboratories, Inc., Hartalega Holdings Berhad, Dynarex Corporation, Braun Melsungen AG, McKesson Medical-Surgical Inc., and CIVCO Medical Solutions.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3822

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

DNA/Gene Microarray Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Traditional solid-phase array and alternative bead array are some of the types of DNA microarray. Major applications of DNA/Gene microarray include, genomics, gene expression, Single Nucleotide Polymorphism (SNP) analysis, and proteomics.

The global DNA/Gene Microarray Market is estimated to account for US$ 3,018.3 Mn in terms of value in 2020 and is expected to reach US$ 7,693.0 Mn by the end of 2027.

Global DNA/Gene Microarray Market: Drivers

Significant developments in personalized medicines is expected to fuel growth of the global DNA/gene microarray market over the forecast period. For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database.

Global DNA/Gene Microarray Market: Opportunities

Increasing investment in DNA sequencing is expected to offer lucrative growth opportunities for players in the market. For instance, in January 2020, Element Biosciences, a biotechnology startup, raised US$ 80 million to develop DNA sequencing platform.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3825

Global DNA/Gene Microarray Market: Restraints

Presence of alternative technologies is expected to hamper growth of the global DNA/gene microarray market. Protein chip and lab-on-chip, glycomic arrays, tissue arrays, and cell arrays are some of the alternatives to DNA/gene microarray.

Key Takeaways:

The global DNA/gene microarray market was valued at US$ 2,640.7 Mn in 2019 and is forecast to reach a value of US$ 7,693.0 Mn by 2027 at a CAGR of 12.4% between 2020 and 2027. The market is expected to witness significant growth owing to increasing technological advancement in microarray technology, and increasing demand for genetic testing.

Gene expression and SNP analysis segment held dominant position in the global DNA/gene microarray market in 2019, accounting for 25.6% share in terms of value, followed by oncology and drug development, respectively. Increasing drug development, and demand for personalized medicine is expected to support growth of the segment over the forecast period.

North America held dominant position in the global DNA/gene microarray market in 2019, accounting for 34.1% share in terms of value, followed by Europe and Asia Pacific, respectively. North America has presence of leading manufacturers, and wide number of research institutes which make use of these products. These factors are expected to support growth of the market over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/dna-gene-microarray-market-3825

Market Trends

The market is witnessing launch of new genetic tests. For instance, in July 2019, MyHeritage, an online genealogy platform with web, mobile, and software products and services, launched new Health+Ancestry test, a health-related genetic test.

The market is also witnessing increasing adoption of nanoarrays, owing to their various advantages in terms of sensitivity, specificity, speed, portability, throughput, and cost. Nanoarrays find application in drug discovery and disease diagnosis.

Global DNA/Gene Microarray Market: Competitive Landscape

Major players operating in the global DNA/gene microarray market include, Affymetrix, Inc., Illumina, Inc., Agilent Technologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix Technology Inc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC, Microarrays Inc.

Global DNA/Gene Microarray Market: Key Developments

Major players in the market are focused on launching new products to expand their product portfolio. For instance, in February 2020, Twist Bioscience Corporation launched the Twist Targeted Methylation Sequencing Solution to study methylation pattern changes in a wide range of research fields including cancer

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in December 2019, Oncology Pharma, Inc. signed a Letter of Intent to acquire at least a 50% stake in Diagnomics, Inc., a private CLIA certified & CAP accredited private molecular Genomics lab and provider of DNA microarrays, Next Generation Sequencing, and real-time PCR solutions

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3825

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Patient Lateral Transfer Devices Market Forecast Opportunity Analysis-2027

Global Patient Lateral Transfer Devices Market, By Product Type (Air Assisted Transfer Device (Regular Mattresses, Split-Leg Mattresses, and Half Mattresses), Slide Sheets, and Transfer Accessories), By Material Type (Single Patient Use and Reusable), By End User (Hospitals, Ambulatory Surgical Centers, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 266.18 million in 2020 and is expected to exhibit a CAGR of 9.4% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Increasing launches of new and advanced patient lateral transfer devices by market players is expected to boost the market growth over the forecast period. For instance, in March 2017, HoverTech International, a provider of air-assisted safe patient handling equipment solutions, introduced the Q2Roller Lateral Turning Device designed to easily turn patients without manual pulling or lifting. The Q2Roller provides an effective solution for caregivers to reposition patients frequently for pressure relief, hygiene, and wound care.

Furthermore, the increasing prevalence of COVID-19 is anticipated to drive the market growth over the forecast period. According to the According to the World Health Organization, around 604,070 cases of coronavirus disease (COVID-19) were reported on April 16, 2020, in the U.S. Such high prevalence of COVID-19 has led to increased hospitalization which resulted in increased demand of patient lateral transfer devices.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3840

Browse 27 Market Data Tables and 26 Figures spread through 201 Pages and in-depth TOC on “Patient Lateral Transfer Devices Market”- Global Forecast to 2027, By Product Type (Air Assisted Transfer Device (Regular Mattresses, Split-leg Mattresses, and Half Mattresses), Slide Sheets, and Transfer Accessories), By Material Type (Single Patient Use and Reusable), By End User (Hospitals, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

Market players are focusing on strengthening their geographical footprint and market presence by increasing investments which is expected to drive the market growth over the forecast period. For instance, in July 2019, Nordstjernan, a subsidiary of Etac, invested 70% of its shares in the HoverTech International, in order to enhance its geographical footprint in patient transfer devices market. Through this investment, Nordstjernan will strengthen its position as a supplier of patient handling equipment in the U.S. market.

Key Takeaways of the Global Patient Lateral Transfer Devices Market:

The global patient lateral transfer devices market is expected to exhibit a CAGR of 9.4% over the forecast period, owing to increasing prevalence of spinal cord injuries (SCI). According to the National Spinal Cord Injury Statistical Center, 2019, around 17,730 new spinal cord injury (SCI) cases are reported in the U.S. every year.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/patient-lateral-transfer-devices-market-3840

Among product type, air assisted transfer device segment accounted for largest market share in 2019, owing to increasing technological advancement in patient lateral transfer devices. For instance, the Evacuation HoverJack II Device, by HoverTech International, is an air assisted all-in-one transport, lift, and stair evacuation solution. The Evacuation HoverJack II Device provides an easy and safer access to healthcare workers in transferring bariatric patients from their home to the hospital.

Among material type, single patient use segment accounted for largest market share in 2019, owing to increasing prevalence of strokes. According to the Global Burden of Disease Stroke Statistics Worldwide, 2016, around 13.7 million new cases of stroke are reported every year globally.

Key players operating in the global patient lateral transfer devices market include Stryker Corporation, Getinge AB, Airpal, Inc., Hovertech International, Hill-Rom Holdings Inc., Sizewise, Patient Positioning System LLC, Medline Industries Inc., EZ Way Inc., McAuley Medical Inc., Air-Matt, Inc., Blue Chip Medical Products Inc., Scan Medical, and Samarit Medical AG.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3840

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

U.S. Implantable Medical Devices Market Size Share Trends Forecast 2026

Active medical implants form a significant portion of the overall implants domain. The most common forms of implantable medical devices are prosthetic devices such as artificial organs, defibrillators, reconstructive joints, spinal implants, intraocular implants, breast implants and others. Implantable medical devices serve two major functions namely, application of a therapy from the inside of an organ and monitoring of the parameters and signals of the functioning of an organ for the optimization of treatment.

The U.S. Implantable Medical Devices Market is estimated to account for US$ 86,446.3 Mn in terms of value in 2020 and is expected to reach US$ 150,299.3 Mn by the end of 2027.

U.S. Implantable Medical Devices Market: Drivers

Increasing approval and launch of new products is expected to propel growth of the U.S. implantable medical devices market over the forecast period. For instance, in April 2020, Axonics Modulation Technologies, Inc. received the U.S. Food & Drug Administration approval for its next generation rechargeable implantable neurostimulator for its r-SNM System under a premarket approval supplement.

U.S. Implantable Medical Devices Market: Opportunities:

Use of additively manufactured and commercially pure biomaterials in medical implants is expected to offer lucrative growth opportunities for players in the market. For instance, in April 2020, researchers from University Medical Centre Utrecht, The Netherlands, reported that bony defects treated with additively manufactured commercially pure titanium implants demonstrated higher volumes of regenerated bone as compared to those treated with commonly used titanium alloy.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3853

U.S. Implantable Medical Devices Market: Restraints

Increasing recall of products is expected to hinder growth of the market. For instance, in February 2019, Medtronic Plc received FDA product recall for implanted cardiac pacemakers, which affected 13,440 devices manufactured and distributed between March 2017 and January 2019.

Key Takeaways:

The U.S. implantable medical devices market was valued at US$ 79,942.0 Mn in 2019 and is forecast to reach a value of US$ 150,299.3 Mn by 2027 at a CAGR of 8.2% between 2020 and 2027. Factors such as increasing prevalence of cardiovascular and orthopaedic ailments, and developments in implantable medical devices technology

Orthopedic Implants held dominant position in the U.S. implantable medical devices market in 2019, accounting for 51.6% share in terms of value, followed by cardiovascular implants and others, respectively. Increasing prevalence of orthopaedic diseases is expected to support growth of the segment over the forecast period. Moreover, product launches in orthopaedic implants segment is further expected to propel growth of the segment.

Market Trends

R&D in medical implants is expected to aid in growth of the market. For instance, in December 2019, researchers from Tufts University, U.S., reported a novel thermal processing method for the direct solid-state molding of regenerated silk into bulk devices with tunable mechanical properties.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/us-implantable-medical-devices-market-3853

Orthobiologics are those substances, which are used for quick healing of bone injuries. These materials are highly instrumental in repairing bone injuries and damages to tendons, muscles and ligaments. Orthobiologic products are made of certain substances already present in the human body. The U.S. is viewed as the largest market for orthobiologics, owing to increasing geriatric population

U.S. Implantable Medical Devices Market: Competitive Landscape

Major players operating in the U.S. implantable medical devices market include Abbott Laboratories, Alcon Laboratories, Biomet Incorporated, Bausch and Lomb Incorporated, Boston Scientific Corporation, Johnson and Johnson, Medtronic Incorporated, St. Jude Medical Incorporated, Smith and Nephew PLC, Stryker Corporation, Synthes Incorporated, and Zimmer Holdings Incorporated.

U.S. Implantable Medical Devices Market: Key Developments

April 2020: Exogenesis Corporation established nanoMesh LLC, a new subsidiary focused on commercialization of the Exogenesis Hernia Mesh, an innovative soft tissue repair implant

March 2020: Establishment Labs Holdings Inc. received the U.S. Patent protecting its proprietary breast implant surface technology

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3853

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737